Clinical trial
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating…
NCT00070564 · SWOG Cancer Research Network, Other · Active, not recruiting
Key facts
| NCT number | NCT00070564 |
|---|---|
| Title | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer |
| Official title | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel |
| Enrollment | 3,294 |
| Start date | Nov 1, 2003 |
| Primary completion | Jan 1, 2015 |
| Completion | Jan 1, 2027 |
| First posted | Oct 7, 2003 |
| Last update posted | Jul 31, 2025 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: